Published in Semin Hematol on May 15, 2014
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica (2015) 1.10
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood (2015) 0.89
Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. PLoS One (2015) 0.88
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. Oncotarget (2017) 0.83
A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. Clin Transl Med (2016) 0.81
Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. Cancer Biol Ther (2016) 0.79
Antigen receptor stereotypy in chronic lymphocytic leukemia. Leukemia (2016) 0.79
A case of SRSF2 mutation in chronic lymphocytic leukemia. Leuk Res Rep (2016) 0.75
Evolution of multiple cell clones over a 29-year period of a CLL patient. Nat Commun (2016) 0.75
PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity. Mol Cell (2016) 0.75
Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma. Trends Genet (2015) 0.75
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol (2017) 0.75
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 11.50
Clonal evolution in cancer. Nature (2012) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Charting a dynamic DNA methylation landscape of the human genome. Nature (2013) 5.80
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer (1981) 4.25
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood (2012) 3.63
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol (2010) 3.26
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet (2012) 3.08
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet (2013) 2.62
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53
The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 2.51
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood (1993) 2.45
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood (2013) 2.18
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2013) 1.93
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
NOTCH1 mutations in CLL associated with trisomy 12. Blood (2011) 1.88
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood (2012) 1.88
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood (2012) 1.79
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood (2009) 1.69
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia (2013) 1.66
Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res (2013) 1.51
Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev (2012) 1.40
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.33
NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia (2012) 1.27
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med (2013) 1.26
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol (2008) 1.24
450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia (2012) 1.23
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res (2012) 1.18
Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol (2012) 1.17
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia (2010) 1.15
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov (2013) 1.11
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood (2014) 1.09
Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia (2012) 1.09
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood (2013) 1.09
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet (2013) 1.08
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol (2012) 1.08
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia (2013) 1.03
Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics (2009) 1.02
The evolutionary biography of chronic lymphocytic leukemia. Nat Genet (2013) 1.02
TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer (2001) 1.01
Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol (2002) 1.00
On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia (2013) 0.99
Towards targeted therapy of chronic lymphocytic leukemia. Adv Exp Med Biol (2013) 0.92
Attenuating homologous recombination stimulates an AID-induced antileukemic effect. J Exp Med (2013) 0.85
Method of the year 2013. Nat Methods (2014) 0.83